Morepen Laboratories: Morepen strengthens integrated CDMO capabilities with first U.S
Morepen Laboratories (MOREPENLAB) filed a disclosure titled "Morepen strengthens integrated CDMO capabilities with first U.S". The company is valued at about ₹6,596 crore.
What happened
Morepen Laboratories (MOREPENLAB) filed a disclosure with the exchanges on 28 September 2026 at 08:56 AM titled "Morepen strengthens integrated CDMO capabilities with first U.S".
Company snapshot
Morepen Laboratories is a small-cap company, with a market value of about ₹6,596 crore.
The stock last traded at ₹120.4, against a 52-week range of ₹33.05–₹126.8 (5.1% below the high).
Before this filing the shares had moved +24.5% over the month and +103.6% over three months. Average daily turnover over the last 20 sessions was about ₹225 crore.
Promoters held 35.65% at the end of Q1 FY27. Foreign institutions owned 1.46% and domestic institutions 1.28%.
What history shows
BCEIE has no earlier approval filing from this company on record since May 2026.
Market-wide, 1,483 approval filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
In the news
Recent coverage elsewhere (links open the original publisher):
- Morepen Laboratories (MOREPENLAB) Share Price Falls 6.25% Today; Valuation and Sector Context in Focus
- We Ran A Stock Scan For Earnings Growth And Morepen Laboratories (NSE:MOREPENLAB) Passed With Ease
- Morepen Laboratories Submits First U.S. ANDA For Sitagliptin Tablets USP In Three Strengths
- Morepen Laboratories shares jump 5% after first US ANDA filing for diabetes drug; zoom 267% in 6 months
- Morepen Laboratories files its first US ANDA for sitagliptin tablets
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.